Mihir Ghonge

Mr. Mihir Ghonge

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
PJPoorva Hemant Joshi
Poorva Hemant Joshi
AYAhmed Adel Ali Youssef
Ahmed Adel Ali Youssef
MGMihir Ghonge
Mihir Ghonge
CVCorinne Varner
Corinne Varner
STSiddharth Tripathi
Siddharth Tripathi
SMSoumyajit Majumdar
Soumyajit Majumdar
Bacterial conjunctivitis (BC) entails inflammation of the ocular mucous membrane. Early effective treatment of BC can prevent the spread of the infection to the intraocular tissues, which could lead to bacterial endophthalmitis or serious visual disability. In 2003, gatifloxacin (GTX) eyedrops were introduced as a new broad-spectrum fluoroquinolone to treat BC. Subsequently, GTX use was extended to other ocular bacterial infections. However, due to precorneal loss and poor ocular bioavailability, frequent administration of the commercial eyedrops is necessary, leading to poor patient compliance. Thus, the goal of the current investigation was to formulate GTX in a lipid-based drug delivery system to overcome the challenges with the existing marketed eyedrops and, thus, improve the management of bacterial conjunctivitis. GTX-NLCs and SLNs were formulated with a hot homogenization–probe sonication method. The lead GTX-NLC formulation was characterized and assessed for in vitro drug release, antimicrobial efficacy (against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa), and ex vivo permeation. The lead formulation exhibited desired physicochemical characteristics, an extended release of GTX over a 12 h period, and was stable over three months at the three storage conditions (refrigerated, room temperature, and accelerated). The transcorneal flux and permeability of GTX from the GTX-NLC formulation were 5.5- and 6.0-fold higher in comparison to the commercial eyedrops and exhibited a similar in vitro antibacterial activity. Therefore, GTX-NLCs could serve as an alternative drug delivery platform to improve treatment outcomes in BC.

10 April 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AYAhmed Adel Ali Youssef
Ahmed Adel Ali Youssef
MAMuna Hayder Abdelrahman
Muna Hayder Abdelrahman
MGMona M. Geweda
Mona M. Geweda
CVCorinne Varner
Corinne Varner
PJPoorva Hemant Joshi
Poorva Hemant Joshi
SMSoumyajit Majumdar
Soumyajit Majumdar

1 May 2023 in Current Drug Delivery
Verified
Journal Article
Closed access
PDF file
HKHarsha Kathpalia
Harsha Kathpalia
SSSaily Shinde
Saily Shinde
MGMihir Ghonge
Mihir Ghonge
On the one hand, oral formulations are susceptible to problems, including instability accompanied by erratic absorption throughout the gastrointestinal tract, first-pass metabolism, and patientrelated and pathological difficulties in consumption. On the other hand, the world has been observing a shift from conventional dermal formulations to the more cosmetically attractive ones. Amid all these, polymeric films and film-forming systems have emerged as promising candidates for addressing the above problems. Oral films have been studied for their potential applications in immediate and sustained- release formulations and have markedly shown increased plasma concentrations of drugs that otherwise undergo degradation in the gastrointestinal tract and the liver and have an obvious edge in treating pathologies of the oral cavity. At the same time, a variety of dermal film formulations have been developed and studied for treating wounds, skin infections and pathologies, corns and calluses, and managing pain. This review article attempts to cover significant findings in oral and dermal applications of these formulations under one umbrella and provide readers with a compilation of relevant research works and marketed formulations.